Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|August 28, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-09-02-2015
- Volume 11
- Issue 9
Technology Allows Automated Lab Reactor Control
Mettler Toledo’s RX-10 Reactor Control automates jacketed lab reactors and controls thermostats, stirrers, and pumps.
The RX-10 Automated Lab Reactor Control from Mettler Toledo controls jacketed lab reactors with third-party heating and cooling systems, liquid addition, stirrers, and process analytical technology (PAT) tools. A touchscreen walk-up interface allows scientists to control reactors on any scale from milliliters to multi-liter.
The reactor control collects data from laboratory reactor equipment and sensors, together with in situ PAT instruments, including pH, particle size analysis, FTIR spectroscopy and chemical reaction sampling.
Experimental sequences and safety limits can be pre-programed so experiments can run overnight. The local touchscreen or PC software offers remote reactor control so scientists can configure all experiment parameters without opening the hood.
RX-10 Reactor Control reduces the time needed to merge and process analytical data, visualize and identify key reaction events and create smart reports.
Source:
Articles in this issue
about 11 years ago
Flow Chemistry Systems Offer Optionsabout 11 years ago
Spectrometers Comply with FDA Electronic Signature Regulationabout 11 years ago
Pressure Reactor for Small Batch Reaction Chemistryabout 11 years ago
Homogenizer Offers Continuous Operationabout 11 years ago
Mayne Pharma to Invest $65m in Manufacturing Expansionabout 11 years ago
Next Step for Elemental Impuritiesabout 11 years ago
WuXi PharmaTech Supplies Laboratory Testing Services to Lee's Pharmabout 11 years ago
Cytovance Biologics Acquired by Hepalinkabout 11 years ago
Industry Responds to FDA Metrics ProgramRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.